nisoldipine has been researched along with Cardiac Failure in 23 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of the second generation calcium channel blocking drug nisoldipine on subjective and objective measurements of exercise performance were studied in 19 patients with moderate to severe heart failure (9 New York Heart Association functional class 2, 9 class 3 and 1 class 4) due to fixed ventricular dysfunction following myocardial infarction." | 9.07 | Effect of nisoldipine on exercise performance in heart failure following myocardial infarction. ( Flugelman, MY; Front, A; Halon, DA; Hardoff, R; Lewis, BS; Makhoul, N; Merdler, A, 1991) |
| "The acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine were studied in patients with chronic heart failure (LV EF < ." | 9.07 | Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. ( Dei Cas, L; Ferrari, R; Metra, M; Visioli, O, 1993) |
| "Afterload reduction with angiotensin-converting enzyme inhibitors (ACE-inhibitors), such as captopril, is an established therapeutic measure in the adjunctive treatment of severe chronic heart failure." | 9.06 | [Clinical and hemodynamic effects of nisoldipine and captopril in heart failure: a double-blind comparative study of long and short-term effects]. ( Figulla, HR; Kreuzer, H; Luig, H; Nieschlag, F, 1987) |
| "To study the haemodynamic and neurohumoral effects of nisoldipine (2 X 10 mg) vs captopril (3 X 25 mg), 24 patients with heart failure (New York Heart Association class II and III) due to coronary artery disease were treated in a randomized double-blind trial over 3 months." | 9.06 | Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. ( Aschenberg, W; Hobuss, M; Schofer, J; Tews, A, 1990) |
| "The acute haemodynamic effects of intravenous nisoldipine and hydralazine were compared in nine patients with heart failure." | 9.06 | Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. ( Angel, ME; Haitas, B; Meyer, TE; Reef, E, 1990) |
| "We studied the acute effects of the calcium antagonist nisoldipine in 10 conscious pigs with chronic heart failure." | 7.68 | Nisoldipine improves blood flow to skeletal muscles in conscious pigs with chronic heart failure. ( Roelandt, JR; Saxena, PR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1990) |
| "Twenty patients (5 females, 15 males) with severe heart failure (NYHA IV), due to coronary artery disease in 14, and congestive cardiomyopathy in 6, received an intravenous bolus of the calcium blocker nisoldipine 0." | 7.68 | Acute haemodynamic and neurohumoral effects of intravenous nisoldipine in patients with severe congestive heart failure. ( Bleifeld, W; Erlemeier, HH; Kupper, W, 1990) |
| "The acute hemodynamic effects of intravenous nisoldipine were studied in 10 patients with severe congestive heart failure." | 7.67 | Intravenous nisoldipine in severe congestive heart failure. ( Armstrong, PW; Frankel, D; Karlinsky, SJ; Moe, GW, 1988) |
| "The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure." | 7.67 | Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989) |
| "Nisoldipine, a calcium entry blocker, was given to 10 patients with congestive heart failure." | 7.67 | Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. ( Barjon, JN; Bichet, D; De Champlain, J; Juneau, C; Rouleau, JL, 1987) |
| "We studied the acute effects of nisoldipine, a new second-generation calcium channel-blocking drug, on cardiac hemodynamics and left ventricular (LV) contractility in 10 patients with grade 2 to 4 cardiac failure." | 7.67 | Effect of the second-generation calcium channel blocker nisoldipine on left ventricular contractility in cardiac failure. ( Flugelman, MY; Halon, DA; Hardoff, R; Lewis, BS; Merdler, A; Shefer, A, 1988) |
| "The systemic and coronary hemodynamic and neurohumoral effects of nisoldipine, a calcium antagonist drug with high vascular specificity, were investigated in 17 patients with chronic congestive heart failure (CHF)." | 7.67 | Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. ( Buehler, FR; Burkart, F; Erne, P; Kiowski, W; Mueller, J; Pfisterer, M, 1987) |
| "Nisoldipine produced an increase in pump function (+2%) in the group with extremely decreased EF up to 9% in some individual cases." | 6.67 | Effects of calcium antagonists in patients with coronary disease and heart failure: left ventricular function following nisoldipine measured by radionuclide ventriculography. ( Eichstaedt, H, 1992) |
| "Nisoldipine produced an increase in LV filling fraction from 36 +/- 17% to 43 +/- 20% (p = 0." | 5.28 | Effect of the second-generation calcium channel blocking drug nisoldipine on diastolic left ventricular dysfunction in heart failure. ( Flugelman, MY; Halon, DA; Hardoff, R; Lewis, BS; Merdler, A; Shefer, A, 1989) |
| "were studied in 15 patients with chronic congestive heart failure due to ischemic heart disease or cardiomyopathy." | 5.27 | Hemodynamic effects of nisoldipine in chronic congestive heart failure. ( Kreuzer, H; Vogt, A, 1983) |
| "A multicentre, double-blind, placebo-controlled trial was conducted in 542 patients, randomized 7-10 days after myocardial infarction, to study the effect of nisoldipine coat-core (nisoldipine-CC) on exercise after 6 months." | 5.08 | Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group. ( , 1997) |
| "The acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine were studied in patients with chronic heart failure (LV EF < ." | 5.07 | Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. ( Dei Cas, L; Ferrari, R; Metra, M; Visioli, O, 1993) |
| "The effects of the second generation calcium channel blocking drug nisoldipine on subjective and objective measurements of exercise performance were studied in 19 patients with moderate to severe heart failure (9 New York Heart Association functional class 2, 9 class 3 and 1 class 4) due to fixed ventricular dysfunction following myocardial infarction." | 5.07 | Effect of nisoldipine on exercise performance in heart failure following myocardial infarction. ( Flugelman, MY; Front, A; Halon, DA; Hardoff, R; Lewis, BS; Makhoul, N; Merdler, A, 1991) |
| "To study the haemodynamic and neurohumoral effects of nisoldipine (2 X 10 mg) vs captopril (3 X 25 mg), 24 patients with heart failure (New York Heart Association class II and III) due to coronary artery disease were treated in a randomized double-blind trial over 3 months." | 5.06 | Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. ( Aschenberg, W; Hobuss, M; Schofer, J; Tews, A, 1990) |
| "The acute haemodynamic effects of intravenous nisoldipine and hydralazine were compared in nine patients with heart failure." | 5.06 | Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. ( Angel, ME; Haitas, B; Meyer, TE; Reef, E, 1990) |
| "By means of impedance- and mechanocardiography the effect of the calcium-channel blocker nisoldipine on the circadian course of hemodynamic parameters was measured in a placebo-controlled randomized double-blind study in 18 patients with heart failure (NYHA II)." | 5.06 | [Mechano- and impedance cardiography parameters in patients with heart failure in administration of a calcium antagonist. The significance of the Heather index]. ( Kirch, W; Linde, M; Ohnhaus, EE, 1989) |
| "Afterload reduction with angiotensin-converting enzyme inhibitors (ACE-inhibitors), such as captopril, is an established therapeutic measure in the adjunctive treatment of severe chronic heart failure." | 5.06 | [Clinical and hemodynamic effects of nisoldipine and captopril in heart failure: a double-blind comparative study of long and short-term effects]. ( Figulla, HR; Kreuzer, H; Luig, H; Nieschlag, F, 1987) |
| "In a placebo controlled double-blind study including 10 patients with heart failure the nisoldipine/digoxin interaction was studied." | 5.06 | Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin. ( Dylewicz, P; Hutt, HJ; Kirch, W; Ohnhaus, EE; Santos, SR; Stenzel, J, 1986) |
| "Twenty patients (5 females, 15 males) with severe heart failure (NYHA IV), due to coronary artery disease in 14, and congestive cardiomyopathy in 6, received an intravenous bolus of the calcium blocker nisoldipine 0." | 3.68 | Acute haemodynamic and neurohumoral effects of intravenous nisoldipine in patients with severe congestive heart failure. ( Bleifeld, W; Erlemeier, HH; Kupper, W, 1990) |
| "We studied the acute effects of the calcium antagonist nisoldipine in 10 conscious pigs with chronic heart failure." | 3.68 | Nisoldipine improves blood flow to skeletal muscles in conscious pigs with chronic heart failure. ( Roelandt, JR; Saxena, PR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1990) |
| "Nisoldipine, a calcium entry blocker, was given to 10 patients with congestive heart failure." | 3.67 | Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. ( Barjon, JN; Bichet, D; De Champlain, J; Juneau, C; Rouleau, JL, 1987) |
| "The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure." | 3.67 | Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989) |
| "We studied the acute effects of nisoldipine, a new second-generation calcium channel-blocking drug, on cardiac hemodynamics and left ventricular (LV) contractility in 10 patients with grade 2 to 4 cardiac failure." | 3.67 | Effect of the second-generation calcium channel blocker nisoldipine on left ventricular contractility in cardiac failure. ( Flugelman, MY; Halon, DA; Hardoff, R; Lewis, BS; Merdler, A; Shefer, A, 1988) |
| "The acute hemodynamic effects of intravenous nisoldipine were studied in 10 patients with severe congestive heart failure." | 3.67 | Intravenous nisoldipine in severe congestive heart failure. ( Armstrong, PW; Frankel, D; Karlinsky, SJ; Moe, GW, 1988) |
| "The systemic and coronary hemodynamic and neurohumoral effects of nisoldipine, a calcium antagonist drug with high vascular specificity, were investigated in 17 patients with chronic congestive heart failure (CHF)." | 3.67 | Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. ( Buehler, FR; Burkart, F; Erne, P; Kiowski, W; Mueller, J; Pfisterer, M, 1987) |
| "Nisoldipine produced an increase in pump function (+2%) in the group with extremely decreased EF up to 9% in some individual cases." | 2.67 | Effects of calcium antagonists in patients with coronary disease and heart failure: left ventricular function following nisoldipine measured by radionuclide ventriculography. ( Eichstaedt, H, 1992) |
| "Nisoldipine produced an increase in LV filling fraction from 36 +/- 17% to 43 +/- 20% (p = 0." | 1.28 | Effect of the second-generation calcium channel blocking drug nisoldipine on diastolic left ventricular dysfunction in heart failure. ( Flugelman, MY; Halon, DA; Hardoff, R; Lewis, BS; Merdler, A; Shefer, A, 1989) |
| "were studied in 15 patients with chronic congestive heart failure due to ischemic heart disease or cardiomyopathy." | 1.27 | Hemodynamic effects of nisoldipine in chronic congestive heart failure. ( Kreuzer, H; Vogt, A, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (56.52) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vogt, A | 1 |
| Kreuzer, H | 2 |
| Dei Cas, L | 1 |
| Metra, M | 1 |
| Ferrari, R | 1 |
| Visioli, O | 1 |
| Schrier, RW | 1 |
| Estacio, RO | 1 |
| Eichstaedt, H | 1 |
| Deleu, D | 1 |
| Bohle, K | 1 |
| Lewis, BS | 3 |
| Makhoul, N | 1 |
| Merdler, A | 3 |
| Flugelman, MY | 3 |
| Front, A | 1 |
| Hardoff, R | 3 |
| Halon, DA | 3 |
| Schofer, J | 1 |
| Hobuss, M | 1 |
| Aschenberg, W | 1 |
| Tews, A | 1 |
| Erlemeier, HH | 1 |
| Kupper, W | 1 |
| Bleifeld, W | 1 |
| Haitas, B | 1 |
| Meyer, TE | 1 |
| Angel, ME | 1 |
| Reef, E | 1 |
| van der Giessen, WJ | 2 |
| van Woerkens, LJ | 2 |
| Saxena, PR | 1 |
| Roelandt, JR | 2 |
| Verdouw, PD | 2 |
| Moe, GW | 1 |
| Karlinsky, SJ | 1 |
| Frankel, D | 1 |
| Armstrong, PW | 1 |
| Duncker, DJ | 1 |
| Linde, M | 2 |
| Ohnhaus, EE | 3 |
| Kirch, W | 3 |
| Shefer, A | 2 |
| Barjon, JN | 1 |
| Rouleau, JL | 1 |
| Bichet, D | 1 |
| Juneau, C | 1 |
| De Champlain, J | 1 |
| Barbieri, L | 1 |
| Mestroni, L | 1 |
| Camerini, F | 1 |
| Figulla, HR | 1 |
| Luig, H | 1 |
| Nieschlag, F | 1 |
| Stenzel, J | 1 |
| Dylewicz, P | 1 |
| Hutt, HJ | 1 |
| Santos, SR | 1 |
| Kiowski, W | 1 |
| Erne, P | 1 |
| Pfisterer, M | 1 |
| Mueller, J | 1 |
| Buehler, FR | 1 |
| Burkart, F | 1 |
| Kimchi, A | 1 |
| Ellrodt, AG | 1 |
| Charuzi, Y | 1 |
| Shell, W | 1 |
| Murata, GH | 1 |
1 review available for nisoldipine and Cardiac Failure
| Article | Year |
|---|---|
[Calcium antagonists in congestive heart failure].
Topics: Calcium Channel Blockers; Cardiomyopathy, Dilated; Diltiazem; Felodipine; Heart Failure; Hemodynamic | 1988 |
10 trials available for nisoldipine and Cardiac Failure
| Article | Year |
|---|---|
Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Exercise; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Ag | 1993 |
Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group.
Topics: Adult; Aged; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Method; Echocardiog | 1997 |
Effects of calcium antagonists in patients with coronary disease and heart failure: left ventricular function following nisoldipine measured by radionuclide ventriculography.
Topics: Acetyldigoxins; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Niso | 1992 |
Effect of nisoldipine on exercise performance in heart failure following myocardial infarction.
Topics: Aged; Double-Blind Method; Exercise Test; Heart Failure; Hemodynamics; Humans; Middle Aged; Myocardi | 1991 |
Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study.
Topics: Adult; Aged; Aldosterone; Captopril; Catecholamines; Child; Double-Blind Method; Female; Heart Failu | 1990 |
Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Heart Failur | 1990 |
[Mechano- and impedance cardiography parameters in patients with heart failure in administration of a calcium antagonist. The significance of the Heather index].
Topics: Aged; Cardiac Output; Cardiography, Impedance; Clinical Trials as Topic; Double-Blind Method; Electr | 1989 |
[Clinical and hemodynamic effects of nisoldipine and captopril in heart failure: a double-blind comparative study of long and short-term effects].
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure; Hemody | 1987 |
The "Heather Index" in impedance cardiography.
Topics: Cardiography, Impedance; Clinical Trials as Topic; Double-Blind Method; Heart Failure; Humans; Middl | 1988 |
Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin.
Topics: Adult; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Digoxin; Double-Blind Method; Femal | 1986 |
12 other studies available for nisoldipine and Cardiac Failure
| Article | Year |
|---|---|
Hemodynamic effects of nisoldipine in chronic congestive heart failure.
Topics: Adult; Calcium Channel Blockers; Heart Failure; Hemodynamics; Humans; Middle Aged; Nifedipine; Nisol | 1983 |
Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 2000 |
Haemodynamic and neurohumoral response to nisoldipine.
Topics: Heart Failure; Hemodynamics; Humans; Neurotransmitter Agents; Nisoldipine | 1991 |
Acute haemodynamic and neurohumoral effects of intravenous nisoldipine in patients with severe congestive heart failure.
Topics: Adult; Aged; Body Surface Area; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; | 1990 |
Nisoldipine improves blood flow to skeletal muscles in conscious pigs with chronic heart failure.
Topics: Adrenal Glands; Animals; Cardiac Output; Chronic Disease; Coronary Circulation; Heart Failure; Hemod | 1990 |
Intravenous nisoldipine in severe congestive heart failure.
Topics: Adult; Aged; Calcium Channel Blockers; Dose-Response Relationship, Drug; Female; Heart Failure; Hemo | 1988 |
Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.
Topics: Acid-Base Equilibrium; Animals; Blood Gas Analysis; Chronic Disease; Heart Failure; Hemodynamics; Ni | 1989 |
Effect of the second-generation calcium channel blocking drug nisoldipine on diastolic left ventricular dysfunction in heart failure.
Topics: Aged; Calcium Channel Blockers; Cardiac Output; Female; Heart; Heart Failure; Humans; Male; Middle A | 1989 |
Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.
Topics: Body Water; Calcium Channel Blockers; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged | 1987 |
Effect of the second-generation calcium channel blocker nisoldipine on left ventricular contractility in cardiac failure.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Cardiac Volume; Heart Failure; Heart | 1988 |
Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy.
Topics: Aged; Calcium Channel Blockers; Cardiomyopathy, Dilated; Coronary Circulation; Forearm; Heart Failur | 1987 |
Salutary hemodynamic and sustained clinical beneficial effects of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure.
Topics: Aged; Calcium Channel Blockers; Coronary Disease; Heart Failure; Hemodynamics; Humans; Male; Mitral | 1985 |